Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study

美波利祖马布 医学 鼻息肉 内科学 嗜酸性粒细胞 哮喘 胃肠病学 鼻窦炎 外科
作者
Stefania Gallo,Paolo Castelnuovo,Luca Spirito,Marta Feduzi,Veronica Seccia,Dina Visca,Antonio Spanevello,Erica Statuti,Francesca Puggioni,Claudio Montuori,Angela Rizzi,Cristina Boccabella,Matteo Bonini,Eugenio De Corso
出处
期刊:Journal of Personalized Medicine [MDPI AG]
卷期号:12 (8): 1304-1304 被引量:22
标识
DOI:10.3390/jpm12081304
摘要

Objective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test (SNOT)-22 score, Nasal Polyp (NP) score, and blood eosinophil count during a 12-month treatment with mepolizumab. Secondary endpoints were to quantify mepolizumab’s effects on the mentioned parameters, identify clinical variables influencing the degree of response to treatment, and portray responder and nonresponder patients. Methods: A multicentric retrospective no-profit observational study on severe asthmatic patients, treated with mepolizumab, and comorbid CRSwNP was conducted. All patients were followed for at least 12 months. SNOT-22 score, NP score, and blood eosinophil count (and other CRS-specific variables) were collected at baseline and after 12 months. Results: Forty-three patients were included. A statistically significant reduction was observed for SNOT-22 score (mean t0 SNOT-22 54.8 ± 25.9; mean t12 SNOT-22 31.5 ± 21.3, p < 0.0001), NP score (median t0 NPS 3 (IQR 3); median t12 NPS 2 (IQR 4), p < 0.0001), and blood eosinophil count (mean t0 blood eosinophils 804.7 ± 461.5 cell/µL; mean t12 blood eosinophils 107.5 ± 104.6 cell/µL, p < 0.0001) after 12 months of treatment. Twenty patients (47%) gained improvement both in clinical and endoscopic outcome. Mepolizumab responder patients presented a t0 SNOT-22 significantly higher than nonresponders (p = 0.0011). Conclusions: Mepolizumab improved CRSwNP outcomes in a population of severe asthmatic patients. No clinical feature emerged to outline the profile of a “typical” responder patient, except for baseline SNOT-22 score, which seemed to affect the response to treatment. Further studies would be necessary to supplement these preliminary evaluations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_Zbb4mZ完成签到,获得积分10
刚刚
刚刚
PrayOne完成签到 ,获得积分10
1秒前
研究牲完成签到,获得积分10
1秒前
2秒前
yufanhui应助Jasin采纳,获得10
2秒前
3秒前
犹豫的踏歌完成签到,获得积分10
3秒前
4秒前
5秒前
7秒前
常常发布了新的文献求助10
7秒前
Sakura发布了新的文献求助10
9秒前
10秒前
苗条伟帮完成签到 ,获得积分10
11秒前
krisliu完成签到 ,获得积分10
11秒前
好大雷完成签到,获得积分10
12秒前
13秒前
冰叶点点完成签到 ,获得积分20
15秒前
可爱的函函应助Sakura采纳,获得10
16秒前
曾经富发布了新的文献求助10
16秒前
NexusExplorer应助科研通管家采纳,获得10
17秒前
搜集达人应助科研通管家采纳,获得10
17秒前
李爱国应助科研通管家采纳,获得10
17秒前
彭于晏应助科研通管家采纳,获得10
17秒前
今后应助科研通管家采纳,获得10
17秒前
yqzhang完成签到,获得积分10
17秒前
adinike发布了新的文献求助10
18秒前
18秒前
嘀嘀嘀完成签到,获得积分10
20秒前
领导范儿应助晓晗采纳,获得10
21秒前
华仔应助孺子采纳,获得10
23秒前
哟哟哟发布了新的文献求助10
24秒前
天天快乐应助小蚊子采纳,获得10
25秒前
嘀嘀嘀发布了新的文献求助30
26秒前
adinike完成签到,获得积分10
27秒前
30秒前
31秒前
Youdge完成签到,获得积分10
32秒前
mmmm应助故笺采纳,获得10
33秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
The Kinetic Nitration and Basicity of 1,2,4-Triazol-5-ones 440
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3159827
求助须知:如何正确求助?哪些是违规求助? 2810718
关于积分的说明 7889262
捐赠科研通 2469826
什么是DOI,文献DOI怎么找? 1315126
科研通“疑难数据库(出版商)”最低求助积分说明 630742
版权声明 602012